Loading...
Loading...
BPMC| Name | Value |
|---|---|
| Revenues | 63.3M |
| Cost of Revenue | 3.2M |
| Gross Profit | 60.1M |
| Operating Expense | 184.3M |
| Operating I/L | -135.4M |
| Other Income/Expense | -4.8M |
| Interest Income | 5.9M |
| Pretax | -129.0M |
| Income Tax Expense | 0.5M |
| Net Income/Loss | -129.6M |
Blueprint Medicines Corporation is a precision therapy company that develops medicines for genomically defined cancers and blood disorders. The company's product pipeline includes AYVAKIT, BLU-263, Fisogatinib, GAVRETO, BLU-701, BLU-945, BLU-451, BLU-782, BLU-222, and BLU-852, targeting various types of cancers and solid tumors. Blueprint Medicines Corporation generates revenue through the development and commercialization of these precision therapies, as well as through collaboration and license agreements with other pharmaceutical companies.
